ADVISORY/ Kenyon & Kenyon - Biotech Court Hearing.

BioTech/Health Care, Business and Legal Reporters

ADVISORY...

--(BUSINESS WIRE)

MEDIA ALERT

Fred Rein, partner with Kenyon & Kenyon, says:

Next week's court hearings between Transkaryotic Therapies (TKTX)

and biotech giant Amgen sets the stage for a competing

Erythropoietin product. Speculation about the outcome of those

hearings is having a significant impact on the Biotech sector on

Wall Street. What are the ramifications of the Erythropoietin

patent case for the biotech industry?

SOURCE: Fred Rein, partner with Kenyon & Kenyon, one of the

nation's leading intellectual property law firms, is available to

provide insight and commentary on this impending hearing and the

ramifications that it may have for the biotech industry. Much of

Mr. Rein's work at Kenyon & Kenyon has been in the area of

pharmaceutical and biotechnology patent litigation and counseling.

Among the important legal/business issues Fred Rein can discuss:

- Why the biotech sector, and its performance on Wall Street, is particularly
sensitive to patent rulings;

- What the potential ramifications are of this hearing for biotech giants like
Amgen and the industry as a whole;

- The likely next steps following the hearing;

Please call with questions or if you would like to speak with Fred Rein.